Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

2.4K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.4K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.2K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

3.5K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.5K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

1.8K
1.8K
Karyotyping01:17

Karyotyping

11.9K
11.9K
Karyotyping01:17

Karyotyping

70.0K
Overview
70.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fabrication and characterization of high-T(c) YBa(2)Cu(3)O(7-x) nanoSQUIDs made by focused ion beam milling.

Nanotechnology·2011
Same author

Thigh muscle volume predicted by anthropometric measurements and correlated with physical function in the older adults.

The journal of nutrition, health & aging·2011
Same author

Effects of operational parameters on decolorisation of C.I. Reactive Black 5 in UV/TiO(2) system.

Water science and technology : a journal of the International Association on Water Pollution Research·2011
Same author

cDNA cloning by inverse polymerase chain reaction.

Methods in molecular biology (Clifton, N.J.)·2011
Same author

Progress toward a synthetic virus : a multicomponent system for liver-directed DNA delivery.

Methods in molecular medicine·2011
Same author

Diagnosis of inflammatory pseudotumour of the urinary bladder aided by dynamic computed tomography.

Acta clinica Belgica·2010

Related Experiment Video

Updated: Mar 28, 2026

Chromosome Preparation From Cultured Cells
07:42

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

84.4K

Additional chromosomal abnormalities in core-binding factor acute myeloid leukemia.

H H Hsiao1,2,3, Y C Liu1,2, H C Wang1

  • 1Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung, Taiwan.

Genetics and Molecular Research : GMR
|December 19, 2015
PubMed
Summary

Additional chromosome abnormalities significantly impact relapse rates in core binding factor acute myeloid leukemia (CBF-AML). These findings highlight the prognostic role of cytogenetic changes in CBF-AML patient outcomes.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.6K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K

Related Experiment Videos

Last Updated: Mar 28, 2026

Chromosome Preparation From Cultured Cells
07:42

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

84.4K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.6K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Core binding factor acute myeloid leukemia (CBF-AML) presents with t(8;21) or inv(16)/t(16;16) but shows variable patient survival.
  • Prognostic factors beyond the primary genetic abnormality are crucial for understanding CBF-AML heterogeneity.

Purpose of the Study:

  • To investigate the impact of cytogenetic abnormalities and specific gene mutations (c-KIT, FLT3, NPM1, CEBPA) on prognosis in CBF-AML patients.
  • To identify factors contributing to the heterogeneous survival observed in CBF-AML.

Main Methods:

  • Analysis of 24 CBF-AML patients.
  • Assessment of cytogenetic abnormalities, including loss of sexual chromosomes (LOS).
  • Evaluation of c-KIT, FLT3, NPM1, and CEBPA mutations.

Main Results:

  • c-KIT and FLT3 mutations were infrequent (12.5% and ~4%, respectively).
  • Over half of patients (14/24) had additional cytogenetic changes, notably loss of sexual chromosomes in the t(8;21) group.
  • Additional chromosome abnormalities were significantly associated with disease relapse (P = 0.027).

Conclusions:

  • c-KIT mutations did not correlate with survival or relapse in this cohort.
  • Additional cytogenetic abnormalities are linked to increased relapse risk in CBF-AML.
  • These findings suggest that chromosomal aberrations contribute to the variable clinical course of CBF-AML.